Britain's Most Admired No. 5: GlaxoSmithKline, Andrew Witty

Witty took over as GSK's boss two years ago, and has been busy reshaping the pharma giant to take better advantage of emerging markets. To that end, he is shifting focus away from traditional high-margin blockbuster drugs to a lower-margin but more diverse and less risky product portfolio. He has also relaxed the firm's notoriously rigid pricing policy to bring much-needed medicines within the budgets of the developing world. The shift seems to be working - Q3 sales are up 15% to £6.8bn.


Sign in to continue

Sign in

Trouble signing in?

Reset password: Click here


Call: 020 8267 8121



  • Up to 4 free articles a month
  • Free email bulletins

Register Now

Become a subscriber

From £66 a quarter

  • Full access to
  • Exclusive event discounts
  • Management Today's print magazine
  • Plus lots more, including our State of the Industry Report.

Choose a Package